JNJ

167.36

+1.16%↑

NVS

115.01

+0.83%↑

ABT

127.26

-0.02%↓

TMO

462

-2.63%↓

ISRG

480.55

-1.3%↓

JNJ

167.36

+1.16%↑

NVS

115.01

+0.83%↑

ABT

127.26

-0.02%↓

TMO

462

-2.63%↓

ISRG

480.55

-1.3%↓

JNJ

167.36

+1.16%↑

NVS

115.01

+0.83%↑

ABT

127.26

-0.02%↓

TMO

462

-2.63%↓

ISRG

480.55

-1.3%↓

JNJ

167.36

+1.16%↑

NVS

115.01

+0.83%↑

ABT

127.26

-0.02%↓

TMO

462

-2.63%↓

ISRG

480.55

-1.3%↓

JNJ

167.36

+1.16%↑

NVS

115.01

+0.83%↑

ABT

127.26

-0.02%↓

TMO

462

-2.63%↓

ISRG

480.55

-1.3%↓

Kodu・Aktsiate loetelu・Pulse Biosciences Inc

Pulse Biosciences Inc

Avatud

SektorTervishoid

14.59 0.62

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.4

Max

15.07

Põhinäitajad
By Trading Economics
Sissetulek	2.6M -17M
Müük	832K 832K
Kasumimarginaal	-2,018.63
Töötajad	75
EBITDA	1.9M -18M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+49.36% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. aug 2025

Turustatistika
By TradingEconomics
Turukapital	-184M 1B
Eelmine avamishind	13.97
Eelmine sulgemishind	14.59

Uudiste sentiment

By Acuity

50%

162 / 375 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

16.59 / 17.17 Toetus ja vastupanu

Pulse Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. juuli 2025, 23:56 UTC

Kuumad aktsiad

Stocks to Watch: Amazon, Bio-Rad, Coinbase, Mercer

31. juuli 2025, 23:48 UTC

Market Talk

Scentre Can Beat Annual Earnings Guidance -- Market Talk

31. juuli 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over Earnings, Domestic Politics -- Market Talk

31. juuli 2025, 23:37 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

31. juuli 2025, 23:37 UTC

Market Talk

Gold Steady as Traders Eye Tariff-Deal Developments -- Market Talk

31. juuli 2025, 23:12 UTC

Tulu

OCBC: Evolving Trade, Monetary Policies, Persistent Geopolitical Tensions Expected to Weigh on Growth Prospects >O39.SG

31. juuli 2025, 23:10 UTC

Tulu

Oversea-Chinese Banking: Declining Interest-Rate Environment Weighed in Net Interest Income >O39.SG

31. juuli 2025, 23:09 UTC

Tulu

Oversea-Chinese Banking 2Q Net Interest Income S$2.28B Vs. S$2.43B >O39.SG

31. juuli 2025, 23:08 UTC

Tulu

Oversea-Chinese Banking 2Q Total Income S$3.55B Vs. S$3.63B >O39.SG

31. juuli 2025, 23:08 UTC

Tulu

Oversea-Chinese Banking 2Q Net S$1.82B Vs. Net S$1.94B >O39.SG

31. juuli 2025, 23:01 UTC

Tulu

Amazon Posts Higher Sales, Profit -- 3rd Update

31. juuli 2025, 22:08 UTC

Market Talk

Tulu

Amazon CEO Impressed by Deals Signed for Project Kuiper -- Market Talk

31. juuli 2025, 22:02 UTC

Market Talk

Tulu

Apple's FY Outlook Shows Sales Growth Won't Last -- Market Talk

31. juuli 2025, 21:57 UTC

Market Talk

Tulu

Amazon CEO Sees Strong Early Demand for Alexa+ -- Market Talk

31. juuli 2025, 21:50 UTC

Tulu

Amazon Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

31. juuli 2025, 21:43 UTC

Tulu

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- 2nd Update

31. juuli 2025, 21:29 UTC

Tulu

Amazon to Invest More in Chips, Data Centers Amid Generative AI Opportunity, CFO Says

31. juuli 2025, 21:26 UTC

Tulu

Apple Expects Revenue to Grow in Mid- to High-Single Digits in Current Quarter, CFO Says

31. juuli 2025, 21:26 UTC

Tulu

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

31. juuli 2025, 21:22 UTC

Tulu

Amazon Has Impressive Amount of Agreements for Project Kuiper, CEO Says

31. juuli 2025, 21:19 UTC

Tulu

Apple Estimates Tariff Impact to Add $1.1B to Costs in Current Quarter, CEO Says

31. juuli 2025, 21:19 UTC

Tulu

Apple Incurred $800M in Tariff-Related Costs in 2Q, CEO Says

31. juuli 2025, 21:14 UTC

Tulu

Amazon's AWS is Seeing More Demand Than Supply, CEO Says

31. juuli 2025, 21:12 UTC

Tulu

Amazon Saw Record Prime Sign-Ups in 3 Weeks Before Prime Day, CEO Says

31. juuli 2025, 21:10 UTC

Tulu

Amazon Just Getting Started on Automation, Robotics to Boost Efficiency, CEO Says

31. juuli 2025, 21:09 UTC

Tulu

Amazon Delivered to Prime Members at Record Pace in 2Q, CEO Says

31. juuli 2025, 21:09 UTC

Tulu

Amazon CEO Sees Diversity of Sellers as Advantage for Inflation-Weary Consumers

31. juuli 2025, 21:08 UTC

Tulu

Apple iPhone Revenue Performance Driven by Popularity of iPhone 16 Family, CEO Says

31. juuli 2025, 21:08 UTC

Tulu

Amazon CEO Sees Strong Customer Adoption of Perishables Same-Day Delivery Pilot

31. juuli 2025, 21:05 UTC

Tulu

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- Update

Võrdlus sarnastega

Hinnamuutus

Pulse Biosciences Inc Prognoos

Hinnasiht

By TipRanks

49.36% tõus

12 kuu keskmine prognoos

Keskmine 22 USD 49.36%

Kõrge 22 USD

Madal 22 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Pulse Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Pulse Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

16.59 / 17.17Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

162 / 375 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.